Swiss Re Ag · SIX:SREN
Swiss Re — Vaccine Webinar 2020
8 slides from Swiss Re's conference presentation, 2020
Slide 1: ivt mRNA: vaccination and gene therapy applications
* * * TRANSIENT ivt mRNA ACGU ivt mRNA Cap1-ACGY VACCINATION (TLR agonist) GENE THERAPY Anti-Cancer Expression of therapeutic protein Anti-Virus e.g. erythropoeitin, antibodies, bispecific Anti-Allergy Cellular reprogramming Genome engineering (Meganuclease, TALEN, CRISPR/CAS9) VACCINATION (i.m.) O’
Slide 2: mRNA is very stable
> mRNA IS VERY STABLE (in the abscence of RNases!) CureVac Wins Two Million EUR from Inaugural European Commission Vaccine Prize TÜBINGEN, Germany/BRUSSELS, Belgium, 10 March 2014 – CureVac, a German clinical stage biopharmaceutical company, today announced that it has won the inaugural European Com
Slide 3: Mumps, measles, rubella and ivt mRNA vaccine
Mumps (attenuated Virus) Measles (attenuated Virus) RNA Lipid Membrane Rubella (attenuated Virus) ivt mRNA vaccine
Slide 4: Production of ivt mRNA
Production of ivt mRNA pDNA Fullfill specifications Starting material RNA polymerase Restriction enzyme DNase Nucleotides Buffers Cap analog First step: Linearisation Restriction enzyme (not needed if PCR) Robust. Two hours Second step: Transcription T7/SP6 RNA polymerase Robust. Two hours HPLC Thir
Slide 5: ivt mRNA therapies: Timelines
ivt mRNA therapies: Timelines Wolff et al describe that direct injection of naked mRNA in mouse muscle gives protein expression Martinon et al use mRNA in liposomes to vaccinate mice Conry et al use naked mRNA to vaccinate mice against cancer Hoerr et al use naked and Protamine formulated mRNA to va
Slide 6: Basic Copyright Notice & Disclaimer
Basic Copyright Notice & Disclaimer ©2020 This presentation is copyright protected. All rights reserved. You may download or print out a hard copy for your private or internal use. You are not permitted to create any modifications or derivatives of this presentation without the prior written permiss
Slide 7: ivt mRNA vaccine against SARS-CoV-2
ivt mRNA vaccine against SARS-CoV-2 in liposomes, intramuscular CureVac: Full Length mutated (2 Prolines to keep “pre-fusion conformation”) Spike, non-modified mRNA, 2mg to 12mg; 12mg per dose in Phase III Moderna: Full Length mutated (2 Prolines to keep “pre-fusion conformation”) Spike, modified mR
Slide 8: Basic Copyright Notice & Disclaimer
Basic Copyright Notice & Disclaimer ©2020 This presentation is copyright protected. All rights reserved. You may download or print out a hard copy for your private or internal use. You are not permitted to create any modifications or derivatives of this presentation without the prior written permiss